Question 3 of 6: Controlling Cell–Surface Interactions and the In Vitro/In Vivo Gap

Question 3: Controlling Cell–Surface Interactions and the In Vitro/In Vivo Gap (20 marks)

Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.

(a) Chemical signalling: a surface can be functionalized with covalently grafted, cell-adhesive peptide sequences derived from native extracellular-matrix proteins — most commonly the RGD (Arg-Gly-Asp) motif from fibronectin/vitronectin, or laminin-derived sequences such as IKVAV — presented via self-assembled monolayers or polymer-brush tethers. Because integrin receptors on the cell membrane recognize these specific short peptide motifs, the density, spacing, and clustering of the grafted ligand directly controls the strength of focal-adhesion formation, cell spreading, migration, and even lineage-specific differentiation (e.g., mesenchymal stem cells differentiate differently depending on RGD ligand spacing and substrate stiffness). More broadly, controlling bulk surface chemistry — wettability, surface charge, and the identity of the first adsorbed protein layer (again via the Vroman-type competitive adsorption discussed in Question 1) — indirectly shapes cell response, since cells rarely contact bare material and instead respond to whatever protein layer has adsorbed onto it.

Topographical signalling: micro- and nano-scale patterning of the surface itself — via photolithography, soft lithography/microcontact printing, electron-beam patterning, laser texturing, or electrospinning of nanofibrous mats — creates grooves, ridges, pillars, or fibre diameters comparable to cellular or sub-cellular (filopodial) length scales. Cells sense this physical geometry through their cytoskeleton (a phenomenon called contact guidance): grooved or fibrous substrates align cell elongation, polarity, and migration direction along the pattern, and nanoscale roughness/pit spacing has been shown to bias stem-cell fate (e.g., osteogenic differentiation on specific nanopit arrangements) independent of any added chemical signal. Chemical and topographical cues are frequently combined in a single scaffold design (e.g., a peptide-grafted, aligned nanofibre mat) because they act through partially independent mechanotransduction and receptor-mediated pathways.

(b) In vitro assays routinely fail to predict in vivo performance because standard cell culture strips away almost everything that makes the in vivo environment what it is: cells are typically grown as a single type in a static, rigid, two-dimensional plastic dish bathed in a constant, artificial medium, with no blood flow or interstitial fluid shear, no mechanical loading cycle, no three-dimensional extracellular-matrix architecture, no resident or infiltrating immune cells (so no foreign-body-response cascade of the kind discussed in Question 4 can occur), no vascular supply or clearance of degradation products, and none of the systemic factors (hormones, circulating cytokines, comorbidities such as diabetes) that shape a real patient's healing response. A material can therefore look completely biocompatible in a static monoculture assay while still provoking a severe chronic foreign-body reaction once it is exposed to a real, dynamically loaded, immunologically active, vascularized tissue bed.

Predictability can be improved by closing these gaps deliberately rather than by simply running the same 2-D assay for longer: culturing cells in three-dimensional, mechanically and biochemically biomimetic hydrogels or bioreactors that reproduce native ECM stiffness and composition; applying physiologically realistic dynamic mechanical loading and fluid shear during culture; using co-cultures that include macrophages/monocytes so that at least the early foreign-body-response cascade can be observed in vitro; and, where a fully in vitro model still cannot capture systemic and immune complexity, validating against a staged sequence of small-animal, then large-animal, models with defined correlation to the intended clinical use, so that in vitro assay results are calibrated against a known in vivo benchmark rather than trusted in isolation.